Meditrina Pharmaceuticals, headquartered in Bucharest, entered the local market in 2009 under the name Solartium. It was founded by three Italian shareholders: Massimo Bonsi, Paolo Giorgetti (a well-known entrepreneur in the Italian pharmaceutical industry) and Prof. Franco Conti, a pharmacologist. In 2011 Solartium became part of SYNAPSIS-MEDITRINA, a pharmaceutical group founded in Cyprus in 2003 and operating in Central and Eastern Europe with offices in Greece, Romania, Bulgaria, Macedonia, Macedonia, Albania, Ukraine and the Republic of Moldova. In 2022, Meditrina Group rebranded its companies, as a result of which Solartium Group was transformed into Meditrina Pharmaceuticals.
Moldova-based Meditrina Pharmaceuticals specializes in dermatology, gynecology, urology and nephrology. It is known for bringing advanced therapies to the market and promoting innovation in healthcare by collaborating with the country’s physicians and pharmacists.
In 2018, the company brought to the market a product for the treatment of urolithiasis, and in 2019 it introduced the first retinoid-based medical product in Moldova that complies with international recommendations for the treatment of acne.
According to public sources, the turnover of Moldova’s Meditrina Pharmaceuticals in 2021 amounted to 3.07 million lei, with a profit of 185.50 thousand lei. In 2022, sales rose to 3.35 million lei, profit fell to 13.50 thousand lei. In 2023, sales amounted to 4.35 million lei, profit 80.24 thousand lei. All this time the company had three employees.
Fidia Farmaceutici, headquartered in Abano Terme, Italy, is a pharmaceutical company specializing in regenerative medicine and the use of hyaluronic acid for therapeutic purposes. The group’s turnover in 2024 amounted to €510 million, an increase of 10% compared to 2023.
Last year, Fidia acquired from Sanofi the rights to manufacture and market a number of products for the gynecology sector, completed the acquisition of Sanifarma, an Italian company that distributes contact lenses, eye drops and dietary supplements, and signed a strategic commercial agreement with Novartis.
